Advertisement
Survey Series
For Advertisers
|
|
||||
|
Sensitizing Cancer Through mTOR
Researchers look to exploit a common weak link in cancer progression
The Scientist 2004, 18(5):30
|
||||
|
|
||||
|
Rapamycin could have been an anti- than tumor contender. Indeed, for more than 30 years, researchers have sized up this immunosuppressant's potential in treating a variety of cancers, including prostate, brain, and lung. Currently, however, the drug is approved only for treating transplant patients. Initial struggles with formulation and the 1982 closure of the original Ayerst laboratory that produced it has kept rapamycin in the background as a cancer therapeutic.
|
|
|||||||||
|
|||||||||
|
